Evidence map›Paper›PMID 22782343›Full record

Trial reportBritish journal of cancer2012

Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.

Z Meng, C R Garrett, Y Shen, L Liu, P Yang, Y Huo, Q Zhao, A R Spelman, C S Ng, D Z Chang and 1 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Chemotherapy and radiotherapy for advanced pancreatic cancer.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Chemotherapy and radiotherapy for advanced pancreatic cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Rapid detection of illegally added nifedipine in Chinese traditional patent medicine by surface-enhanced Raman spectroscopy.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Z MengDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
C R Garrett
Y Shen
L Liu
P Yang
Y Huo
Q Zhao
A R Spelman
C S Ng
D Z Chang
L Cohen
The University of Texas MD Anderson Cancer Center · USFudan University Shanghai Cancer Center · CNFudan University · CNShanghai Medical College of Fudan University · CN

Funding

International Center of TCM for CancerU19CA121503 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI COHEN, LORENZO · 2005 to 2010
$3.0M
NCI NIH HHS U19 CA121503NCI NIH HHS U19CA121503-01
6 · The paper itself

Abstract

backgroundAn intravenous formulated extract of the venom of the wild toad Bufo bufo gargarizans Cantor or Bufo melanostictus Schneider, huachansu, is currently used in China for the treatment of lung, liver, pancreatic, and colorectal cancers. We performed a randomised, single-blinded, phase II clinical study of huachansu plus gemcitabine versus placebo plus gemcitabine in patients with locally advanced and/or metastatic pancreatic adenocarcinomas.

methodsPatients with tissue-proven locally advanced and/or metastatic pancreatic adenocarinoma were randomly assigned to receive either gemcitabine 1000 mg m(-2) on days 1, 8, and 15 with huachansu 20 ml m(-2) daily for 21 days (arm A) or placebo (arm B); treatment cycles were 28 days in length. Primary end point was 4-month progression-free overall survival (PFS); secondary end points were objective radiographical response rate (ORR), time to progression (TTP), and toxicity.

resultsA total of 80 subjects were enrolled; 76 patients were evaluable (received at least 1 week therapy). Median overall survival was 160 days for arm A and 156 days for arm B (P=0.339); ORR was 9 and 3% in arms A and B, respectively (P=0.332), median TTP was 98 and 115 days, respectively (P=0.825); the median 4-month PFS was 99 and 98 days, respectively (P=0.679).

conclusionHuachansu when combined with gemcitabine did not improve the outcome of patients with locally advanced and/or metastatic pancreatic cancer.

Indexed as

AdenocarcinomaAmphibian VenomsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAnuraDeoxycytidineDisease-Free SurvivalFemaleGemcitabineHumansMaleMedicine, Chinese TraditionalMiddle AgedPancreatic NeoplasmsProspective StudiesSingle-Blind MethodAmphibian VenomsDeoxycytidineGemcitabinehuachansu

Identifiers

PMID22782343
PMCPMC3405220
OpenAlexW1995070503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.